Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Lymphangioleiomyomatosis × Sirolimus × Clear all

Phase

Phase 2 4 Phase 3 2 Phase 1 2 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Multiple Myeloma 7 Hematologic Neoplasms 7 Graft vs Host Disease 5 Myelodysplastic Syndromes 4 Sarcoma 3 Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 Lymphoma, Non-Hodgkin 3 Leukemia, Myeloid, Acute 3 Leukemia, Lymphocytic, Chronic, B-Cell 3 Leukemia 3 Gliosarcoma 3 Glioblastoma 3 Brain Neoplasms 3 Waldenstrom Macroglobulinemia 2 Tuberous Sclerosis 2 Prostatic Neoplasms 2 Neurofibrosarcoma 2 Myeloproliferative Disorders 2 Lymphoma, Mantle-Cell 2 Lymphoma, Follicular 2 Lymphoma, B-Cell, Marginal Zone 2 Lymphoma 2 Lung Neoplasms 2 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2 Hodgkin Disease 2 Carcinoma, Non-Small-Cell Lung 2 Burkitt Lymphoma 2 Bronchiolitis Obliterans Syndrome 2 Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1

Interventions

carbon-11 acetate 1 Sirolimus 1 Simvastatin 1 Imatinib Mesylate 1 Everolimus 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02061397 2020-08-25

SOS

University of Pennsylvania

Phase 1/2 Completed

10 enrolled 6 charts

Tuberous Sclerosis, Lymphangioleiomyomatosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡